



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

6018

GARDELLA et al.

Art Unit:

1646

Appl. No.:

09/475,158

Examiner:

Ruixiang, Li

Filed:

December 30, 1999

Atty. Docket:

Confirmation No.:

0609.4780001/LBB/M-G

For:

PTH Functional Domain Conjugate Peptides, Derivatives Thereof and Novel Tethered Ligand-Receptor

Molecules

Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated May 4, 2004, Applicants submit the following Amendment and Reply. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.